Boryung Corporation

KOSE:A003850 Stock Report

Market Cap: ₩727.4b

Boryung Past Earnings Performance

Past criteria checks 1/6

Boryung has been growing earnings at an average annual rate of 10.5%, while the Pharmaceuticals industry saw earnings growing at 4.8% annually. Revenues have been growing at an average rate of 13.8% per year. Boryung's return on equity is 6.9%, and it has net margins of 5.5%.

Key information

10.55%

Earnings growth rate

6.13%

EPS growth rate

Pharmaceuticals Industry Growth11.32%
Revenue growth rate13.81%
Return on equity6.90%
Net Margin5.49%
Last Earnings Update30 Sep 2025

Recent past performance updates

Additional Considerations Required While Assessing Boryung's (KRX:003850) Strong Earnings

Mar 21
Additional Considerations Required While Assessing Boryung's (KRX:003850) Strong Earnings

Recent updates

Additional Considerations Required While Assessing Boryung's (KRX:003850) Strong Earnings

Mar 21
Additional Considerations Required While Assessing Boryung's (KRX:003850) Strong Earnings

We Think Boryung (KRX:003850) Is Taking Some Risk With Its Debt

Sep 20
We Think Boryung (KRX:003850) Is Taking Some Risk With Its Debt

Earnings Not Telling The Story For Boryung Corporation (KRX:003850)

Aug 05
Earnings Not Telling The Story For Boryung Corporation (KRX:003850)

Why We're Not Concerned About Boryung Corporation's (KRX:003850) Share Price

Apr 06
Why We're Not Concerned About Boryung Corporation's (KRX:003850) Share Price

A Look At The Fair Value Of Boryung Pharmaceutical Co., Ltd. (KRX:003850)

Apr 28
A Look At The Fair Value Of Boryung Pharmaceutical Co., Ltd. (KRX:003850)

Boryung Pharmaceutical (KRX:003850) Has A Pretty Healthy Balance Sheet

Mar 17
Boryung Pharmaceutical (KRX:003850) Has A Pretty Healthy Balance Sheet

Here's How We Evaluate Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Dividend

Feb 27
Here's How We Evaluate Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Dividend

Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Feb 09
Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?

Jan 25
Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?

Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?

Jan 10
Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?

If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns

Dec 23
If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns

Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?

Dec 08
Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?

Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?

Nov 23
Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?

Revenue & Expenses Breakdown

How Boryung makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A003850 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 251,028,99356,447211,88559,821
30 Jun 251,020,01231,801213,43856,156
31 Mar 251,024,05646,580217,36254,712
31 Dec 241,017,10769,633217,19851,469
30 Sep 24991,43061,995230,06053,328
30 Jun 24928,71864,579223,42252,073
31 Mar 24889,41652,254220,64150,585
31 Dec 23859,62640,203214,85447,286
30 Sep 23829,85428,267201,65641,603
30 Jun 23819,46338,284200,15441,415
31 Mar 23785,67942,063195,42740,249
31 Dec 22760,47641,894191,85841,705
30 Sep 22724,65953,911184,42243,444
30 Jun 22694,17052,524178,67641,373
31 Mar 22661,94834,380173,97240,604
31 Dec 21627,27943,044171,81839,146
30 Sep 21600,00841,823167,98536,053
30 Jun 21587,35028,892167,01135,884
31 Mar 21571,59438,370159,08336,957
31 Dec 20561,86726,856148,22435,506
30 Sep 20562,43327,744144,70436,253
30 Jun 20546,97427,969140,38339,247
31 Mar 20539,74231,678140,14136,934
31 Dec 19524,26932,222139,54437,864
30 Sep 19498,00632,950127,56036,683
30 Jun 19480,24229,886124,85534,458
31 Mar 19467,44522,830125,22135,580
31 Dec 18460,40220,307122,20434,433
30 Sep 18441,58064,630107,69558,302
30 Jun 18440,08762,855115,35949,298
31 Mar 18434,56560,451127,96332,997
31 Dec 17422,72156,699127,66632,277
30 Sep 17426,554-3,202145,0237,366
30 Jun 17423,777-2,977137,32814,638
31 Mar 17420,1335,020120,81929,164
31 Dec 16409,1405,614121,77828,963

Quality Earnings: A003850 has a large one-off loss of ₩23.7B impacting its last 12 months of financial results to 30th September, 2025.

Growing Profit Margin: A003850's current net profit margins (5.5%) are lower than last year (6.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A003850's earnings have grown by 10.5% per year over the past 5 years.

Accelerating Growth: A003850's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A003850 had negative earnings growth (-9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-16.4%).

Return on Equity

High ROE: A003850's Return on Equity (6.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/26 21:09
End of Day Share Price 2025/11/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Boryung Corporation is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Myung Sun LeeDB Financial Investment Co. Ltd.
Hyung Soo KimKyobo Securities Co., Ltd
Seung-woo SeoMirae Asset Securities Co., Ltd.